21 Nov 2012, BioSpectrum Bureau , BioSpectrum
Singapore: US-based YM BioSciences, a drug development company advancing hematology and cancer related products, appointed Dr Kapil Dhingra to the company's board of directors. Dr Dhingra was also recently appointed to the board of Median Technologies.
Dr Dhingra has 25 years of experience in oncology clinical research and drug development. Previously, Dr Dhingra held the position of VP, head, oncology disease biology leadership team, Roche, playing a key role in the expansion of Roche oncology.
He is currently the MD of KAPital Consulting, a healthcare consulting firm he founded in June 2008 dedicated to assisting biotechnology, pharmaceutical and diagnostic companies realize the full potential of scientific, clinical and commercial advances in oncology. He serves on the board of a number of companies, including Exosome Diagnostics and Algeta.
Throughout his career, Dr Dhingra maintained an active faculty appointment, initially at Indiana University School of Medicine from 1997-99 as clinical associate professor and more recently at Memorial Sloan Kettering Cancer Center in New York from 2000 to 2008. Dr Dhingra received his medical training at the All India Institute of Medical Sciences, New Delhi, India.